ImmuPharma

Business news, market intelligence, and global industry analysis.

The Latest

Representative image of a United States Navy unmanned surface vessel operating near a naval warship, illustrating the US Navy’s MASC programme cancellation and the launch of the $2.1 billion MUSV marketplace under the Golden Fleet strategy.

US Navy cancels MASC programme, launches $2.1bn MUSV marketplace as the Golden Fleet strategy moves from concept to procurement

No Kings protests return to New York City for third time as nationwide mobilisation targets Trump administration policies

Representative image of the BA.3.2 “Cicada” COVID variant under surveillance as the Centers for Disease Control and Prevention tracks detections across 25 United States states and the World Health Organization flags potential immune escape risk.

CDC tracks BA.3.2 Cicada COVID variant across 25 US states as WHO flags immune escape risk

A small imaging trial could reshape how brain metastases are detected and Radiopharm Theranostics is betting on it (ASX: RAD)

ImmuPharma (AIM: IMM) advances P140 patent and partnering push with new study data and peer-review manuscript in preparation

ImmuPharma's P140 clears UK patent examination as new study data and Bio-Europe partner meetings strengthen the 2026 licensing case. Read the full analysis.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

March 28, 2026